Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________________________________
FORM 6-K
______________________________________________________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
June 2019
______________________________________________________________________
Commission File Number: 001-38067
______________________________________________________________________
Verona Pharma plc
(Exact Name of Registrant as Specified in Its Charter)
______________________________________________________________________
3 More London Riverside
London SE1 2RE UK
+44 203 283 4200
(Address of principal executive office)
______________________________________________________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On May 29, 2019, Verona Pharma plc (the "Company") issued a press release reporting the purchase of shares by Kayt Morgan, spouse of Mr. Piers Morgan, CFO of the Company (the Person Discharging Managerial Responsibilities ("PDMR") announcement, the ("PDMR Announcement")).
The PDMR Announcement is furnished herewith as Exhibit 1 to this Report on Form 6-K.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
| | | | | | | |
| | | | | | | |
| VERONA PHARMA PLC |
| | | |
Date: June 5, 2019 | | | By: | | /s/ Claire Poll |
| | | | | Name: | | Claire Poll |
| | | | | Title: | | Legal Counsel |
| | | |
Exhibit
Verona Pharma plc
PDMR Dealing
May 29, 2019, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that, on May 28, 2019, Kayt Morgan, spouse of Mr. Piers Morgan, CFO of the Company, purchased 33,802 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 59 pence per Ordinary Share and a total purchase price of £19,954.18. Following the acquisition, Mr. Morgan will have a beneficial interest in the Company of 147,009 Ordinary Shares, representing 0.14% of the Company’s issued share capital.
This purchase brings the total purchases by Mr. and Mrs. Morgan during the past few months to over £52,000 and follows the purchases made by the Company’s Chairman, Dr. David Ebsworth, in March totaling approximately £50,000.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
|
| | |
1 | Details of the person discharging managerial responsibilities/person closely associated |
a) | Name | Kayt Morgan |
2 | Reason for the notification |
a) | Position/status | Spouse (PCA) of Piers Morgan, Chief Financial Officer |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) | Name | Verona Pharma plc |
b) | LEI | 213800EVI6O6J3TIAL06 |
|
| | | | | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 5 pence each GB00BYW2KH80 |
b) | Nature of the transaction | Purchase of Ordinary Shares |
c) | Price(s) and volume(s) | Price(s)
59 pence per Ordinary Share | Volume(s)
33,802 Ordinary Shares |
d) | Aggregated information - Aggregated volume - Price | N/A |
e) | Date of the transaction | May 28, 2019 |
f) | Place of the transaction | London Stock Exchange, AIM |
For further information, please contact:
|
| |
Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer Victoria Stewart, Director of Communications | info@veronapharma.com |
| |
N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 3283 4200 |
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance) Mia Gardner (Corporate Broking) | |